[{"orgOrder":0,"company":"FibroBiologics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CYWC628","moa":"","graph1":null,"graph2":null,"graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"FibroBiologics \/ FibroBiologics","highestDevelopmentStatusID":null,"companyTruncated":"FibroBiologics \/ FibroBiologics"}]

Find Clinical Drug Pipeline Developments & Deals by FibroBiologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).

                          Brand Name : CYWC628

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 18, 2024

                          Lead Product(s) : CYWC628

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Recipient : Charles River Laboratories, Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank